HALO: Halozyme Inc. Analyst Consensus Forecast

Symbol and logo of brand Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics (HALO) is implementing ESG standards in the development of oncology drugs, while business sustainability relies on US enzyme development centers and licensing payments from pharma behemoths. This chart on GURU.Markets shows that the current indicator is 120.47. Halozyme Therapeutics (HALO) maintains a monopoly in subcutaneous drug delivery methods, allowing partners to extend patent lives and ensuring a stable stream of income for the company.

Halozyme Inc. - HALO Price Target Chart (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Halozyme Inc. (HALO)

- share price and consensus valuation forecast:
Price Performance Chart halozyme.com|HALO - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Halozyme Inc.|HALO - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Halozyme|HALO - Company Book Value|Market-to-Book Ratio halozyme.com|HALO - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Halozyme Therapeutics|HALO - Long-Term Debt to Capital|Short-Term Debt to Capital Halozyme Corp|HALO - Company Debts|Debt to Book Value Ratio Halozyme Inc.|HALO - Company Long-Term Debts|Company Current Liabilities Halozyme|Immediate Liquidity halozyme.com
- financial results and valuation multiples details:
HALO - Company Net Income|Expected Net Income Halozyme Therapeutics|HALO - Price to Earnings Ratio|Future Price to Earnings Multiple Halozyme Therapeutics, Inc.|HALO - PEG Multiple|Enterprise Value to EBITDA Ratio Halozyme Inc.|HALO - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Halozyme|HALO - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months halozyme.com|HALO - Earnings growth in current year|Expected net earnings per share growth next year Halozyme Therapeutics
Fundamental company analysis:halozyme.com (HALO)
Original product of Halozyme Inc.

Investments in the elite team of biochemists at Halozyme Therapeutics (HALO) ensure technological leadership in drug delivery, laying the foundation for long-term business value. Analyzing the overall consensus valuation of the stock, an investor sees a gap between the market price and the average fair value estimate from experts, where a significant discount signals either an undervalued asset or hidden development risks for the company.

Competing companies

ONC (beigene.com) - Fair Value Consensus|Analyst Consensus Forecast RVMD (Revolution Medicines, Inc.)|Analyst Consensus Forecast Ascentage Pharma Group International AAPG|CGON - Price Target Chart|URGN: Price Target Chart|Bicara Therapeutics Inc. (BCAX) - Price Target Chart|Average Forecast Price personalis.com (PSNL)|ERAS (Erasca) - Analyst Consensus Forecast|Consensus Target Delcath Systems Inc (DCTH)|Analyst Consensus Forecast YMAB|Analyst Consensus Forecast Aura Corp (AURA)|Price Target Chart Candel Therapeutics, Inc. CADL|ARAY: Broker Consensus Forecast|SELLAS Life Sciences Group Inc. - Analyst Consensus Forecast|Actuate Therapeutics Inc. (ACTU) - Consensus Target|CTOR: Analyst Consensus Forecast|Average Forecast Price TuHURA Biosciences (HURA)|Price Target Chart Protara Therapeutics|FATE: Fair Value Consensus|Consensus Target WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Fair Value Consensus|Analyst Consensus Forecast CSBR (Champions Oncology, Inc.)|XBIT - Consensus Target|CVM: Consensus Target|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Analyst Consensus Forecast TPST|XLO (xiliotx.com) - Fair Value Consensus|Analyst Consensus Forecast RENB (Renovaro)|Analyst Consensus Forecast Mural Oncology PLC MURA|KAPA - Price Target Chart|OKUR: Price Target Chart|w2.cytomed.sg (GDTC) - Price Target Chart|Average Forecast Price Curis (CRIS)|Consensus Target APLM|Tharimmune Inc - Forecast Levels Chart|Consensus Target ADVB (Advanced Biomed Inc)|GNPX - Average Forecast Price|Price Target Chart Calidi Biotherapeutics, Inc. CLDI|SBFM - Consensus Target|Xenetic Bio - Analyst Consensus Forecast|Average Forecast Price Salarius Pharmaceuticals Inc|PPBT (Purple Biotech Corp) - Consensus Target|American Oncology Network, Inc. - Fair Value Consensus|Consensus Target BGNE|CKPT (checkpointtx.com) - Analyst Forecast Prices|Analyst Consensus Forecast ELEV|ICAD (icadmed.com) - Fair Value Consensus|Analyst Consensus Forecast IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Average Forecast Price|VIRX - Price Target Chart|Fair Value Consensus MOR (morphosys.com)|NAYA: Analyst Consensus Forecast|Ascentage Pharma Group International (AAPGV) - Analyst Consensus Forecast